BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 25600841)

  • 1. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
    Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
    Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
    Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y
    BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Jean SS; Lee WS; Yu KW; Liao CH; Hsu CW; Chang FY; Ko WC; Chen RJ; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Lam C; Liu CY; Hsueh PR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):969-976. PubMed ID: 25661253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum β-lactamases.
    Ku YH; Lee MF; Chuang YC; Chen CC; Yu WL
    J Microbiol Immunol Infect; 2015 Dec; 48(6):699-702. PubMed ID: 24388585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
    Johnson JK; Robinson GL; Pineles LL; Ajao AO; Zhao L; Albrecht JS; Harris AD; Thom KA; Furuno JP
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
    Mody RM; Erwin DP; Summers AM; Carrero HA; Selby EB; Ewell AJ; Moran KA
    Ann Clin Microbiol Antimicrob; 2007 Jun; 6():6. PubMed ID: 17553151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
    Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam.
    Cheng NC; Liu CY; Huang YT; Liao CH; Teng LJ; Hsueh PR
    J Antimicrob Chemother; 2012 Jun; 67(6):1413-21. PubMed ID: 22345386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
    Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
    Fernández-Canigia L; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2012 Oct; 11():29. PubMed ID: 23088592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan.
    Chang YY; Chuang YC; Siu LK; Wu TL; Lin JC; Lu PL; Wang JT; Wang LS; Lin YT; Huang LJ; Fung CP
    J Microbiol Immunol Infect; 2015 Apr; 48(2):219-25. PubMed ID: 25074627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.